Pharma investors, wake up you idiots, mRNA is a busted flush
Don't believe all you read in the papers
Recycling is a good thing
I’m recycling some posts from the earlier days of Inside Pharma, as the passage of time has added weight to the content.
Here’s a starter for 10:
Pharma investors—gene therapy is not the golden goose you think it is
INSIDE PHARMA is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Investors piling into gene therapy In May, I posted about the need for investors to be wary about the profit potential for pharmaceutical products based on gene therapy. It refers to an article penned by me and Daniel O’C…
This is what my thinking was then, and still is today:
Gene therapy has been a flop and is set to continue as such, once the COVID mRNA feeding frenzy subsides
SARS-CoV-2 breathes new life into gene therapy, but that can only be short lived—as with any investment, the fundamentals of affordable products with a robust route to market must be there.
Much as UK Government, the MHRA, and anyone else, wave through gene therapy as the great white hope, remember it is destined to be just another white elephant, without proper attention to the current problems.
Critical thinkers on the medicinal products they and their loved ones are asked to take, would do well to shout this loud and clear, wherever they can.
Then we have this little gem below, where ‘Expert Speakers’ share their lack of concern for what happens to the people that get jabs: